DoW Pancreatic Cancer Research Program, Focused Pilot Award
Dept. of Defense — CDMRP · Other Federal · HT942526PCARPFPTA
Source: Grants.gov · View original posting ↗
- AwardWhat a single award can be worth — the funder's published per-award amount or floor–ceiling range.
- $1.2M total
- DeadlineFinal application due date.
- Oct 7, 2026
- Letter of intentDue date for the letter of intent (a short pre-application some funders require or request before the full proposal).
- —
- MechanismNIH activity code — the grant type (R01 research project, R21 exploratory, K series career development, F series fellowship, …).
- —
- DurationMaximum project period for a single award.
- —
- Expected awardsHow many awards the funder anticipates making under this opportunity.
- 4
- Funding cycleHow often the program accepts applications (annual, multiple cycles per year, rolling, or one-time).
- Unknown
- Open dateWhen applications open (or opened).
- May 4, 2026
- Total fundingThe overall pool the funder expects to commit across ALL awards under this opportunity — not what one project receives.
- $1.2M total
- Clinical trialWhether proposed projects must, may, or must not include a clinical trial.
- Unspecified
Research areas
Auto-classified from the title and description (keyword-based) — may be imperfect.
Description
Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Focused Pilot Award supports the exploration and development of impactful and innovative concepts under a patient-centered focus area of pancreatic cancer research that could ultimately lead to major advancements that will have a profound effect on patients’ overall quality of life. The research this award supports should strive to produce robust preliminary data that can serve as a foundation for future clinical or real-world research application. Distinctive Features: This award mechanism allows, but does not require, preliminary data. Applications can support clinical research studies; however, this mechanism does not allow clinical trials. Preclinical animal studies do not meet the intent of this mechanism.